- Home
- JKHY vs NBIX Comparison
JKHY vs NBIX Comparison
Compare JKHY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- NBIX
- Stock Information
- Founded
- JKHY 1976
- NBIX 1992
- Country
- JKHY United States
- NBIX United States
- Employees
- JKHY N/A
- NBIX N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JKHY Technology
- NBIX Health Care
- Exchange
- JKHY Nasdaq
- NBIX Nasdaq
- Market Cap
- JKHY 12.1B
- NBIX 11.0B
- IPO Year
- JKHY N/A
- NBIX 1996
- Fundamental
- Price
- JKHY $180.96
- NBIX $115.71
- Analyst Decision
- JKHY Hold
- NBIX Strong Buy
- Analyst Count
- JKHY 9
- NBIX 20
- Target Price
- JKHY $184.22
- NBIX $163.20
- AVG Volume (30 Days)
- JKHY 662.0K
- NBIX 1.8M
- Earning Date
- JKHY 05-06-2025
- NBIX 05-05-2025
- Dividend Yield
- JKHY 1.28%
- NBIX N/A
- EPS Growth
- JKHY 13.10
- NBIX N/A
- EPS
- JKHY 5.87
- NBIX 2.96
- Revenue
- JKHY $2,319,828,000.00
- NBIX $2,412,600,000.00
- Revenue This Year
- JKHY $9.18
- NBIX $15.36
- Revenue Next Year
- JKHY $7.28
- NBIX $16.34
- P/E Ratio
- JKHY $30.80
- NBIX $39.66
- Revenue Growth
- JKHY 5.92
- NBIX 21.73
- 52 Week Low
- JKHY $157.00
- NBIX $84.23
- 52 Week High
- JKHY $196.00
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- JKHY 62.74
- NBIX 60.88
- Support Level
- JKHY $164.18
- NBIX $105.45
- Resistance Level
- JKHY $177.67
- NBIX $130.46
- Average True Range (ATR)
- JKHY 4.00
- NBIX 4.31
- MACD
- JKHY 0.95
- NBIX 1.96
- Stochastic Oscillator
- JKHY 96.33
- NBIX 50.22
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.